This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Immunologic Disorders  • Journalology/ Peer Review/ Authorship  • Conflict of Interest  • Rheumatoid Arthritis  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We acknowledge that the disclosure statement initially prepared at the time of the original submission of our article¹ to JAMA in May 2005 was incomplete and required correction.²

We further acknowledge that there were 4 opportunities for the disclosure to be made correctly during the several iterations of the manuscript as it went through the review process. We apologize to the readers and the editors of JAMA for the error.

The manuscript was reviewed, per written agreement, by representatives of Abbott, but not by Centocor, with whom no such agreement exists. As stated in our original disclosure, we received no support from any pharmaceutical company for this study.

Because of our incomplete and erroneous disclosures in the JAMA article, Mayo Clinic has conducted an internal investigation and specified remedial activities for us to pursue. As a result of that investigation, we disclose that about 7 months after . . . [Full Text of this Article]

Eric L. Matteson, MD, MPH
matteson.eric@mayo.edu

Tim Bongartz, MD
Division of Rheumatology
Mayo Clinic College of Medicine
Rochester, Minn

RELATED ARTICLE

Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials
Tim Bongartz, Alex J. Sutton, Michael J. Sweeting, Iain Buchan, Eric L. Matteson, and Victor Montori
JAMA. 2006;295(19):2275-2285.
ABSTRACT | FULL TEXT